Mirati Therapeutics, Inc. 26M.F Stock
Mirati Therapeutics, Inc. Price Chart
Mirati Therapeutics, Inc. 26M.F Financial and Trading Overview
Mirati Therapeutics, Inc. stock price | 53.3 EUR |
Previous Close | 33.59 EUR |
Open | 35.14 EUR |
Bid | 35.17 EUR x 50000 |
Ask | 36.05 EUR x 50000 |
Day's Range | 35.14 - 35.14 EUR |
52 Week Range | 33.4 - 95 EUR |
Volume | 40 EUR |
Avg. Volume | 2 EUR |
Market Cap | 2.04B EUR |
Beta (5Y Monthly) | 1.019366 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 222.67 EUR |
26M.F Valuation Measures
Enterprise Value | 1.17B EUR |
Trailing P/E | N/A |
Forward P/E | -2.7388933 |
PEG Ratio (5 yr expected) | 0.07 |
Price/Sales (ttm) | 108.21889 |
Price/Book (mrq) | 2.3687227 |
Enterprise Value/Revenue | 61.838 |
Enterprise Value/EBITDA | -1.526 |
Trading Information
Mirati Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.019366 |
52-Week Change | -28.39% |
S&P500 52-Week Change | 20.43% |
52 Week High | 95 EUR |
52 Week Low | 33.4 EUR |
50-Day Moving Average | 37.95 EUR |
200-Day Moving Average | 52.67 EUR |
26M.F Share Statistics
Avg. Volume (3 month) | 2 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 58.19M |
Float | 36.53M |
Short Ratio | N/A |
% Held by Insiders | 6.76% |
% Held by Institutions | 115.17% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -4071.10% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -39.16% |
Return on Equity (ttm) | -69.80% |
Income Statement
Revenue (ttm) | 18.89M EUR |
Revenue Per Share (ttm) | 0.33 EUR |
Quarterly Revenue Growth (yoy) | 910.89% |
Gross Profit (ttm) | -519791000 EUR |
EBITDA | -765819008 EUR |
Net Income Avi to Common (ttm) | -737067008 EUR |
Diluted EPS (ttm) | -12.24 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 907.67M EUR |
Total Cash Per Share (mrq) | 15.6 EUR |
Total Debt (mrq) | 51.13M EUR |
Total Debt/Equity (mrq) | 5.93 EUR |
Current Ratio (mrq) | 7.539 |
Book Value Per Share (mrq) | 14.835 |
Cash Flow Statement
Operating Cash Flow (ttm) | -600283008 EUR |
Levered Free Cash Flow (ttm) | -316056256 EUR |
Profile of Mirati Therapeutics, Inc.
Country | Germany |
State | CA |
City | San Diego |
Address | 3545 Cray Court |
ZIP | 92121 |
Phone | 858 332 3410 |
Website | https://www.mirati.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 587 |
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Q&A For Mirati Therapeutics, Inc. Stock
What is a current 26M.F stock price?
Mirati Therapeutics, Inc. 26M.F stock price today per share is 53.3 EUR.
How to purchase Mirati Therapeutics, Inc. stock?
You can buy 26M.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mirati Therapeutics, Inc.?
The stock symbol or ticker of Mirati Therapeutics, Inc. is 26M.F.
Which industry does the Mirati Therapeutics, Inc. company belong to?
The Mirati Therapeutics, Inc. industry is Biotechnology.
How many shares does Mirati Therapeutics, Inc. have in circulation?
The max supply of Mirati Therapeutics, Inc. shares is 71.14M.
What is Mirati Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Mirati Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Mirati Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Mirati Therapeutics, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Mirati Therapeutics, Inc. company belong to?
The Mirati Therapeutics, Inc. sector is Healthcare.